Pfizer Inc. (NYSE:PFE) Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,068,300 shares of the biopharmaceutical company's stock after selling 162,000 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Pfizer were worth $52,411,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Pfizer in the fourth quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. increased its position in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Starboard Value LP purchased a new position in shares of Pfizer in the fourth quarter valued at $407,730,000. Raymond James Financial Inc. purchased a new position in shares of Pfizer in the fourth quarter valued at $274,694,000. Finally, Assenagon Asset Management S.A. increased its position in Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Trading Down 1.3%

NYSE:PFE traded down $0.33 during mid-day trading on Friday, reaching $24.51. The company's stock had a trading volume of 46,354,360 shares, compared to its average volume of 41,209,115. The company's fifty day simple moving average is $23.06 and its two-hundred day simple moving average is $24.95. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a market cap of $139.35 billion, a P/E ratio of 17.38, a P/E/G ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company earned $0.82 EPS. The firm's quarterly revenue was down 7.8% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.02%. The ex-dividend date was Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.